BridgeBio Pharma (NASDAQ:BBIO)’s stock price rose 5.5% on Thursday after Goldman Sachs Group raised their price target on the stock from $43.00 to $52.00. The stock traded as high as $39.78 and last traded at $39.60. Approximately 480,103 shares changed hands during trading, a decline of 34% from the average daily volume of 728,991 shares. The stock had previously closed at $37.52.
BBIO has been the subject of several other research reports. Zacks Investment Research lowered shares of BridgeBio Pharma from a “hold” rating to a “sell” rating in a report on Friday, August 14th. Bank of America started coverage on shares of BridgeBio Pharma in a research note on Thursday, June 25th. They issued a “neutral” rating and a $38.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of BridgeBio Pharma in a research note on Wednesday, August 12th. ValuEngine lowered BridgeBio Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 15th. Finally, BidaskClub raised BridgeBio Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $44.60.
In other news, insider Cameron Turtle sold 2,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.06, for a total transaction of $92,650.00. Following the transaction, the insider now directly owns 15,068 shares in the company, valued at $558,420.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian C. Stephenson sold 4,661 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $27.27, for a total transaction of $127,105.47. Following the completion of the transaction, the insider now directly owns 289,855 shares of the company’s stock, valued at approximately $7,904,345.85. The disclosure for this sale can be found here. Insiders sold a total of 174,975 shares of company stock valued at $5,793,984 over the last quarter. Company insiders own 40.32% of the company’s stock.
The business’s 50-day moving average price is $32.44 and its 200-day moving average price is $30.18. The company has a current ratio of 9.30, a quick ratio of 9.30 and a debt-to-equity ratio of 1.43. The stock has a market cap of $4.59 billion, a PE ratio of -12.76 and a beta of 0.61.
BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.27). As a group, analysts predict that BridgeBio Pharma will post -3.65 earnings per share for the current year.
BridgeBio Pharma Company Profile (NASDAQ:BBIO)
BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Featured Story: Momentum Indicators
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.